Plain-English translation of NCT05342493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term safety study of AJOVY, an injectable medication for migraine prevention. Researchers want to understand how safe this treatment is when people use it over extended periods in everyday life. The study will also collect information about how well the medication works for reducing migraine symptoms.
While this medication has been tested before, researchers need to monitor its safety in real-world use over longer periods—especially how it affects the heart and blood vessels. This information helps doctors make sure the treatment remains safe for patients using it long-term.
You likely qualify if…
You likely don't qualify if…
You would receive regular injections of the medication as prescribed and attend study visits to check on your health and any side effects. The study team will ask you questions about your migraines, how you're feeling, and any health changes you notice. This is a long-term study with about 1,000 participants, so you would be part of a large group helping researchers understand real-world safety.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Japan
Enrollment target
~1,000 participants
Started
April 2022
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
Otsuka Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.